KIT (KIT proto-oncogene, receptor tyrosine kinase)

MSCs, CPCs, and their combination are associated with selective, time-dependent modulation of inflammatory and matrix remodeling biomarkers in ischemic heart failure. These findings provide mechanistic insight into cell therapy effects and identify PDGF-BB, PTX3, TNF-α, MMP-1, and BMP-9 as candidate biomarkers for response monitoring and hypothesis generation in future regenerative trials.

FLCN-mutated RCCs comprise a morphologically heterogeneous yet molecularly defined group. Conventional oncoytic morphology was associated with germline alterations while unclassified morphologies could be associated with somatic alterations and possibly germline mutations. FLCN mutations may also be incidental germline mutations in other RCC subtypes. Tumors with unclassified morphologies evoked morphological and immunohistochemical diagnostic consideration of other oncocytic and papillary RCCs and could be associated with adverse outcomes. Recognition may be aided by diffuse GPNMB expression, but definitive classification, especially in cases without conventional morphology, requires molecular testing. These findings broaden the spectrum of FLCN-driven tumors and support their distinction as a unique molecular entity.

This study suggests that LOT may originate from principal cells of the collecting duct and distal renal tubule. Morphologically, it is characterized by a nested growth pattern with stromal edema, and immunohistochemically, it shows positivity for CK7 and negativity for CD117. The consistent positive expression of L1CAM in this study serves as a useful complementary marker for the differential diagnosis of LOT from other morphologically similar eosinophilic renal tumors. Regarding molecular genetics, this study not only explored the characteristics of mTOR pathway gene mutations in LOT but also identified one case with non-mTOR pathway-related molecular alterations, providing new supplementary information for the molecular landscape of LOT. Considering the cellular origin and indolent biological behavior of LOT, these findings contribute to further refinement of the classification system and nomenclature for this type of tumor. Additionally, this study provides important case data supporting LOT in the Chinese population.

Postoperatively, the patient received only 1 year of adjuvant imatinib (400 mg/day) and remained disease-free for the subsequent 14 years, until liver lesions were incidentally identified during a routine physical examination...This case is clinically distinctive owing to its ultra-long recurrence interval and synchronous bifocal hepatic metastasis, thereby offering valuable insights into the long-term natural course of GISTs in the setting of inadequate adjuvant tyrosine kinase inhibitor (TKI) therapy. Furthermore, it underscores the necessity of long-term postoperative surveillance for patients with GIST and highlights the potential role of comprehensive genetic testing in guiding individualized treatment decisions.

ETBF and its secreted toxin fragilysin suppress Lgr5 ⁺ stem cells while directly promoting multipotency of c-Kit ⁺ DCS cells via Wnt signaling. Collectively, our findings identify diet-driven gut microbial shifts as a key regulator of stem cell plasticity, linking environmental exposure to epithelial reprogramming and colorectal cancer risk.

P2, N=46, Recruiting, Kumquat Biosciences Inc. | Not yet recruiting --> Recruiting

Given the patient's advanced age and underlying MF, two cycles of a low-intensity chemotherapy regimen primarily based on the "VP regimen (Vincristine + Prednisone) combined with Azacitidine" were administered...Patient tolerability to intensive chemotherapy and novel targeted agents (e.g., Venetoclax) is poor, leading to a dismal prognosis...This case not only serves as a unique model illustrating the complex evolution of a malignant clone but also profoundly reveals the unique therapeutic challenges and extremely poor survival outcome resulting from the convergence of advanced age, MF background, and MPAL transformation. It offers pivotal real-world evidence for the clinical management of this specific patient population and highlights the need to explore novel therapeutic strategies.

Although rare, gastric schwannoma should be considered in the differential diagnosis of gastric subepithelial tumours. Accurate pathological diagnosis is essential to guide appropriate management and avoid unnecessary oncologic treatment.

ALK and FANCA were linked to increased hazard, while EP300 and PIK3R1 mutations correlated with improved prognosis. Given the growing importance of biomarker-driven treatment in the field of oncology, our results collectively open up new therapeutic opportunities for ES NSCLC patients.

Prognosis in TETs relies primarily on histology and staging, whereas molecular and immunological biomarkers represent emerging tools for risk stratification and treatment selection. Multiparametric models integrating clinical, pathological, and molecular data may pave the way for precision oncology in TETs.

Novel therapeutic approaches are emerging, including PRMT5 inhibitors in MTAP-deficient tumors, TROP-2-directed antibody-drug conjugates (e.g., sacituzumab govitecan), and chimeric antigen receptor (CAR) T-cell therapies targeting mesothelin. Bispecific agents such as bintrafusp alfa and ivonescimab, which co-target various pathways, offer innovative strategies. Despite these advances, TC remains a challenging malignancy with no standardized treatment algorithm. Collaborative efforts across institutions will be essential to accelerate progress and improve outcomes in this rare disease.

A comprehensive evaluation that incorporates clinical history, advanced imaging modalities-including magnetic resonance imaging and ^99mTc-labeled heat-damaged red blood cell scintigraphy-as well as multidisciplinary consultation, can enhance diagnostic accuracy and help prevent overtreatment. Current evidence indicates that asymptomatic splenosis does not necessitate surgical intervention, and precise preoperative recognition is crucial for optimizing patient management.